{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T02:20:07Z","timestamp":1773109207048,"version":"3.50.1"},"reference-count":83,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:00:00Z","timestamp":1606003200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["175014"],"award-info":[{"award-number":["175014"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["175093"],"award-info":[{"award-number":["175093"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Clin Pract"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1111\/ijcp.13825","type":"journal-article","created":{"date-parts":[[2020,11,6]],"date-time":"2020-11-06T15:46:11Z","timestamp":1604677571000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["An overview of antiviral strategies for coronavirus 2 (SARS\u2010CoV\u20102) infection with special reference to antimalarial drugs chloroquine and hydroxychloroquine"],"prefix":"10.1155","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1979-0762","authenticated-orcid":false,"given":"Viktorija","family":"Dragojevic Simic","sequence":"first","affiliation":[{"name":"Center for Clinical PharmacologyMilitary Medical Academy Belgrade Serbia"},{"name":"Faculty of Medicine Military Medical AcademyUniversity of Defence Belgrade Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milijana","family":"Miljkovic","sequence":"additional","affiliation":[{"name":"Center for Clinical PharmacologyMilitary Medical Academy Belgrade Serbia"},{"name":"Faculty of Medicine Military Medical AcademyUniversity of Defence Belgrade Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-1966","authenticated-orcid":false,"given":"Dusica","family":"Stamenkovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Military Medical AcademyUniversity of Defence Belgrade Serbia"},{"name":"Department of Anesthesiology and Intensive Care Military Medical Academy Belgrade Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2458-2282","authenticated-orcid":false,"given":"Berislav","family":"Vekic","sequence":"additional","affiliation":[{"name":"Department of Surgery Clinical Center Dr. Dragisa Misovic Kragujevac Serbia"},{"name":"Faculty of Medical Sciences University of Kragujevac Kragujevac Serbia"},{"name":"Ministry of Health of the Republic of Serbia Belgrade Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nenad","family":"Ratkovic","sequence":"additional","affiliation":[{"name":"Faculty of Medicine Military Medical AcademyUniversity of Defence Belgrade Serbia"},{"name":"Sector for Treatment Military Medical Academy Belgrade Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radoje","family":"Simic","sequence":"additional","affiliation":[{"name":"Department for Plastic Surgery Institute for Mother and Child Health Care of Serbia Dr. Vukan Cupic Belgrade Serbia"},{"name":"Faculty of Medicine University of Belgrade Belgrade Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-8094","authenticated-orcid":false,"given":"Nemanja","family":"Rancic","sequence":"additional","affiliation":[{"name":"Center for Clinical PharmacologyMilitary Medical Academy Belgrade Serbia"},{"name":"Faculty of Medicine Military Medical AcademyUniversity of Defence Belgrade Serbia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,11,22]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-020-00646-x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.7861\/clinmed.2019-coron"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2020.102433"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2020.032"},{"key":"e_1_2_10_6_1","unstructured":"Severe acute respiratory infections treatment Centre: practical manual to set up and manage a SARI treatment centre and SARI screening facility in health care facilities. Geneva: World Health Organization;2020.https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/331603\/WHO\u20102019\u2010nCoV\u2010SARI_treatment_center\u20102020.1\u2010eng.pdf?sequence=1&isAllowed=y. Accessed June 23 2020."},{"key":"e_1_2_10_7_1","unstructured":"UpToData: McIntosh K Hirsch M Bloom A. Coronavirus disease 2019 (COVID\u201019): Clinical features;2020.https:\/\/www.uptodate.com\/contents\/coronavirus\u2010disease\u20102019\u2010covid\u201019. Accessed June 23 2020."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25766"},{"key":"e_1_2_10_9_1","volume-title":"Features, Evaluation and Treatment Coronavirus (COVID\u201019)","author":"Cascella M","year":"2020"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25707"},{"key":"e_1_2_10_11_1","unstructured":"LiuW LiH. COVID\u201019: attacks the 1\u2010beta chain of hemoglobin and captures the porphyrin to inhibit human heme metabolism. [ChemRxivTM\u2010Preprint].https:\/\/chemrxiv.org\/articles\/COVID\u201019_Disease_ORF8_and_Surface_Glycoprotein_Inhibit_Heme_Metabolism_by_Binding_to_Porphyrin\/11938173. Accessed June 28 2020."},{"key":"e_1_2_10_12_1","first-page":"38","article-title":"Treatment of Covid\u201019 Infection. A Rationale for current and future pharmacological approach","volume":"9","author":"Popov D","year":"2020","journal-title":"EC Pulmonol Respir Med"},{"key":"e_1_2_10_13_1","unstructured":"Rebelem:RezaiS. COVID\u201019: Clinical\/therapeutic staging proposal and treatment; 2020.https:\/\/rebelem.com\/covid\u201019\u2010clinical\u2010therapeutic\u2010staging\u2010proposal\u2010and\u2010treatment\/. Accessed June 22 2020."},{"key":"e_1_2_10_14_1","unstructured":"World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID\u201019 disease is suspected: interim guidance;2020.https:\/\/apps.who.int\/iris\/handle\/10665\/331446?search\u2010result=true&query=10665%2F331446&scope=&rpp=10&sort_by=score&order=desc. Accessed June 22 2020."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40779-020-0233-6"},{"key":"e_1_2_10_16_1","unstructured":"Johns Hopkins University Coronavirus Resource Center. Mortality Analyses.https:\/\/coronavirus.jhu.edu\/data\/mortality. Accessed June 22 2020."},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30183-5"},{"key":"e_1_2_10_18_1","unstructured":"World Health Organization. Novel coronavirus (2019\u2010nCoV) situation Report\u20148;2020.https:\/\/www.who.int\/docs\/default\u2010source\/coronaviruse\/situation\u2010reports\/20200128\u2010sitrep\u20108\u2010ncov\u2010cleared.pdf?sfvrsn=8b671ce5_2. Accessed June 20 2020."},{"key":"e_1_2_10_19_1","unstructured":"Liverpul drug interactions group. Interactions with experimental COVID\u201019 Therapies;2020.https:\/\/www.sefq.es\/_pdfs\/CV19_19.pdf. Accessed June 20 2020."},{"key":"e_1_2_10_20_1","unstructured":"Medicines and Medical Devices Agency of Serbia. Summary of product characteristics: Aluvia\u00ae: lopinavir\/ritonavir;2019.https:\/\/www.alims.gov.rs\/ciril\/files\/lekovi\/smpc\/515\u201001\u201002931\u201018\u2010001.pdf. Accessed June 20 2020."},{"key":"e_1_2_10_21_1","unstructured":"Medicines and Medical Devices Agency of Serbia. Summary of product characteristics: Actemra\u00ae: tocilizumab;2019.https:\/\/www.alims.gov.rs\/ciril\/files\/lekovi\/smpc\/515\u201001\u201002510\u201019\u2010001.pdf. Accessed June 20 2020."},{"key":"e_1_2_10_22_1","unstructured":"Medicines and Medical Devices Agency of Serbia. Summary of product characteristics: Copegus\u00ae: ribavirin;2019.https:\/\/www.alims.gov.rs\/ciril\/files\/lekovi\/smpc\/515\u201001\u201001427\u201018\u2010001.pdf. Accessed June 20 2020."},{"key":"e_1_2_10_23_1","unstructured":"ClinicalTrials.gov. Tocilizumab in COVID\u201019 pneumonia (TOCIVID\u201019).https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04317092. Accessed June 29 2020."},{"key":"e_1_2_10_24_1","unstructured":"Drugs.com. Atazanavir side effects. Last updated on May 24 2019.https:\/\/www.drugs.com\/sfx\/atazanavir\u2010side\u2010effects.html. Accessed June 29 2020."},{"key":"e_1_2_10_25_1","unstructured":"Drugs.com. Hydroxychloroquine;2020.https:\/\/www.drugs.com\/ppa\/hydroxychloroquine.html. Accessed June 29 2020."},{"key":"e_1_2_10_26_1","unstructured":"Drugs.com. Chloroquine side effects;2019.https:\/\/www.drugs.com\/sfx\/chloroquine\u2010side\u2010effects.html. Accessed June 29 2020."},{"key":"e_1_2_10_27_1","unstructured":"European Medicines Agency. Summary of product characteristics: IntronA: recombinant interferon alfa\u20102b.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/introna\u2010epar\u2010product\u2010information_en.pdf. Accessed June 29 2020."},{"key":"e_1_2_10_28_1","unstructured":"BerginC PhilbinM GilvarryP O\u2019ConnorM KingF.Protocol: Specific Antiviral Therapy in the Clinical Management of Acute Respiratory Infection with SARSCoV\u20102 (COVID\u201019);2020.https:\/\/www.hse.ie\/eng\/about\/who\/acute\u2010hospitals\u2010division\/drugs\u2010management\u2010programme\/guidelines\/specific\u2010antiviral\u2010therapy\u2010in\u2010the\u2010clinical\u2010management\u2010of\u2010acute\u2010respiratory\u2010infection\u2010with\u2010sars\u2010cov\u20102\u2010covid\u201019.pdf. Accessed June 29 2020."},{"key":"e_1_2_10_29_1","unstructured":"European Medicines Agency. Summary of product characteristics: Ribavirin Teva Pharma B.V: ribavirin.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/ribavirin\u2010teva\u2010pharma\u2010bv\u2010epar\u2010product\u2010information_en.pdf. Accessed June 27 2020."},{"key":"e_1_2_10_30_1","unstructured":"European Medicines Agency. Summary of product characteristics: Reyataz: atazanavir.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/reyataz\u2010epar\u2010product\u2010information_en.pdf. Accessed June 27 2020."},{"key":"e_1_2_10_31_1","unstructured":"Van IersselS DaubyN BottieauE. Interim clinical guidance for adults with suspected or confirmed covid\u201019 in Belgium;2020. Version 7.https:\/\/covid\u201019.sciensano.be\/sites\/default\/files\/Covid19\/COVID\u201019_InterimGuidelines_Treatment_ENG.pdf. Accessed May 20 2020."},{"key":"e_1_2_10_32_1","unstructured":"SmithT BushekJ LeClaireA ProsserT. COVID\u201019 drug therapy;2020.https:\/\/www.elsevier.com\/__data\/assets\/pdf_file\/0007\/988648\/COVID\u201019\u2010Drug\u2010Therapy_2020\u20106\u201017.pdf. Accessed May 20 2020."},{"key":"e_1_2_10_33_1","unstructured":"Instruction for medical use of arbidol.http:\/\/www.arbidol.org\/dosage.pdf. Accessed May 20 2020."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105954"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0282-0"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1617020114"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature17180"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.20153"},{"key":"e_1_2_10_39_1","unstructured":"Ministry of Health Serbia. Diagnosis & Treatment Protocol for COVID\u201019;2020. [Internal Document]."},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa478"},{"key":"e_1_2_10_41_1","unstructured":"Van IersselS DaubyN BottieauE. Interim Clinical Guidance for adults with suspected or confirmed covid\u201019 in Belgium;2020. Version 9.https:\/\/covid\u201019.sciensano.be\/sites\/default\/files\/Covid19\/COVID\u201019_InterimGuidelines_Treatment_ENG.pdf. Accessed May 30 2020."},{"key":"e_1_2_10_42_1","unstructured":"National Institutes of Health: COVID\u201019 Treatment Guidelines. Coronavirus Disease 2019 (COVID\u201019) treatment guidelines;2020.https:\/\/www.covid19treatmentguidelines.nih.gov\/. Accessed June 30 2020."},{"key":"e_1_2_10_43_1","first-page":"969","volume-title":"Goodman and Gilman\u2019s Pharmacological basis of therapeutics","author":"Vinetz JM","year":"2018"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(10)80012-5"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(03)00806-5"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4615-1325-4_31"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1099\/0022-1317-80-2-297"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/1743-422X-2-69"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2004.08.085"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature02145"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11427-020-1637-5"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)91269-X"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa237"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(83)91265-2"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(65)90050-5"},{"key":"e_1_2_10_56_1","first-page":"800","article-title":"Laboratory studies of the 4\u2010aminoquinoline antimalarials. I Some biochemical characteristics of chloroquine, hydroxychloroquine and SN\u20107718","volume":"11","author":"McChesney EW","year":"1961","journal-title":"Antibiot Chemother"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2020.03.011"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2016.01.058"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-015-0239-y"},{"key":"e_1_2_10_60_1","first-page":"ciaa394","article-title":"Towards optimization of hydroxychloroquine dosing in intensive care unit COVID\u201019 patients","author":"Perinel S","year":"2020","journal-title":"Clin Infect Dis"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.5582\/bst.2020.01047"},{"key":"e_1_2_10_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105949"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.03.005"},{"key":"e_1_2_10_64_1","article-title":"Role of chloroquine and hydroxychloroquine in the treatment of COVID\u201019 infection\u2014A systematic literature review","author":"Kapoor KM","year":"2020","journal-title":"MedRxiv"},{"key":"e_1_2_10_65_1","first-page":"185","article-title":"Multicenter collaboration group of Department of Science and Technology of Guangdong Province and Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus pneumonia","volume":"43","author":"Jie Z","year":"2020","journal-title":"Expert Consensus on Chloroquine Phosphate for the Treatment of Novel Coronavirus Pneumonia"},{"key":"e_1_2_10_66_1","first-page":"215","article-title":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID\u201019","volume":"49","author":"Chen J","year":"2020","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"e_1_2_10_67_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1849"},{"key":"e_1_2_10_68_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.8857"},{"key":"e_1_2_10_69_1","unstructured":"ChenZ HuJ ZhangZ JiangS HanS YanD et al.Efficacy of hydroxychloroquine in patients with COVID\u201019: results of a randomized clinical trial.MedRxiv.2020. [Preprint].https:\/\/www.medrxiv.org\/content\/10.1101\/2020.03.22.20040758v3. Accessed June 28 2020."},{"key":"e_1_2_10_70_1","unstructured":"Medicines & Healthcare products Regulatory Agency. Chloroquine and Hydroxychloroquine not licensed for coronavirus (COVID\u201019) treatment;2020.https:\/\/www.gov.uk\/government\/news\/chloroquine\u2010and\u2010hydroxychloroquine\u2010not\u2010licensed\u2010for\u2010coronavirus\u2010covid\u201019\u2010treatment. Accessed May 30 2020."},{"key":"e_1_2_10_71_1","unstructured":"U.S. Food and Drug Administration. FDA cautions against use of hydroxychloroquine or chloroquine for COVID\u201019 outside of the hospital setting or a clinical trial due to risk of heart rhythm problems.https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010cautions\u2010against\u2010use\u2010hydroxychloroquine\u2010or\u2010chloroquine\u2010covid\u201019\u2010outside\u2010hospital\u2010setting\u2010or. Accessed May 30 2020"},{"key":"e_1_2_10_72_1","unstructured":"European Medicines Agency. Science Medical Health. COVID\u201019: chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes; 2020.https:\/\/www.ema.europa.eu\/en\/news\/covid\u201019\u2010chloroquine\u2010hydroxychloroquine\u2010only\u2010be\u2010used\u2010clinical\u2010trials\u2010emergency\u2010use\u2010programmes. Accessed May 30 2020."},{"issue":"20","key":"e_1_2_10_73_1","first-page":"31180","article-title":"RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID\u201019: a multinational registry analysis","volume":"0140","author":"Mehra MR","year":"2020","journal-title":"Lancet"},{"key":"e_1_2_10_74_1","unstructured":"World Health Organization. \u201cSolidarity\u201d clinical trial for COVID\u201019 treatments;2020.https:\/\/www.who.int\/emergencies\/diseases\/novel\u2010coronavirus\u20102019\/global\u2010research\u2010on\u2010novel\u2010coronavirus\u20102019\u2010ncov\/solidarity\u2010clinical\u2010trial\u2010for\u2010covid\u201019\u2010treatments. Accessed May 30 2020."},{"key":"e_1_2_10_75_1","unstructured":"RECOVERY Randomized evaluation of COVID\u201019 Therapy. Recruitment to the RECOVERY trial continues as planned.2020.https:\/\/www.recoverytrial.net\/news\/recruitment\u2010to\u2010the\u2010recovery\u2010trial\u2010continues\u2010as\u2010planned. Accessed May 30 2020."},{"key":"e_1_2_10_76_1","unstructured":"RECOVERY Randomized evaluation of COVID\u201019 Therapy. Randomized evaluation of COVID 19 therapy.https:\/\/www.recoverytrial.net\/files\/recovery\u2010protocol\u2010v6\u20100\u20102020\u201005\u201014.pdf. Accessed June 15 2020."},{"key":"e_1_2_10_77_1","unstructured":"POLITICO. France bans use of hydroxychloroquine as coronavirus treatment.2020.https:\/\/www.politico.com\/news\/2020\/05\/27\/france\u2010bans\u2010use\u2010of\u2010hydroxychloroquine\u2010to\u2010cure\u2010coronavirus\u2010283724. Accessed June 15 2020."},{"key":"e_1_2_10_78_1","unstructured":"COVID\u201019: l\u2019ANSM souhaite suspendre par pr\u00e9caution les essais cliniques \u00e9valuant l\u2019hydroxychloroquine dans la prise en charge des patients\u2014Point d'Information;2020.https:\/\/www.ansm.sante.fr\/S\u2010informer\/Points\u2010d\u2010information\u2010Points\u2010d\u2010information\/COVID\u201019\u2010l\u2010ANSM\u2010souhaite\u2010suspendre\u2010par\u2010precaution\u2010les\u2010essais\u2010cliniques\u2010evaluant\u2010l\u2010hydroxychloroquine\u2010dans\u2010la\u2010prise\u2010en\u2010charge\u2010des\u2010patients\u2010Point\u2010d\u2010Information. Accessed on June 1 2020."},{"key":"e_1_2_10_79_1","unstructured":"National Institutes of Health. NIH halts clinical trial of hydroxychloroquine;2020.https:\/\/www.nih.gov\/news\u2010events\/news\u2010releases\/nih\u2010halts\u2010clinical\u2010trial\u2010hydroxychloroquine. Accessed June 22 2020."},{"key":"e_1_2_10_80_1","first-page":"1","article-title":"Chloroquine\u2010induced QTc prolongation in COVID\u201019 patients","author":"Broek MPH","year":"2020","journal-title":"Neth Heart J"},{"key":"e_1_2_10_81_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012410"},{"key":"e_1_2_10_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2016638"},{"key":"e_1_2_10_83_1","unstructured":"World Health Organization.Guidance for managing ethical issues in infectious disease outbreaks. Spain: World Health Organization;2016.https:\/\/apps.who.int\/iris\/handle\/10665\/250580. Accessed May 30 2020."},{"key":"e_1_2_10_84_1","doi-asserted-by":"publisher","DOI":"10.7326\/M20-1334"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijcp.13825","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijcp.13825","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijcp.13825","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:11:56Z","timestamp":1643350316000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijcp.13825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,22]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.1111\/ijcp.13825"],"URL":"https:\/\/doi.org\/10.1111\/ijcp.13825","archive":["Portico"],"relation":{},"ISSN":["1368-5031","1742-1241"],"issn-type":[{"value":"1368-5031","type":"print"},{"value":"1742-1241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,22]]},"assertion":[{"value":"2020-07-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}